Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies (Q38229636)

31 August 2017

Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies (English)

1 reference

chronic renal insufficiency

31 August 2017

1 reference

Lucia Del Vecchio

1

1 reference

PubMed ID

25025373

31 August 2017

Francesco Locatelli

series ordinal

2

1 reference

31 August 2017

1 August 2014

1 reference

Expert Review of Hematology

31 August 2017

1 reference

31 August 2017

7

1 reference

31 August 2017

495-506

1 reference

31 August 2017

4

1 reference

Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones

31 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Haemoglobin levels and health-related quality of life: a neglected hard end point.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Inflammation and resistance to treatment with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Ferric carboxymaltose: a review of its use in iron-deficiency anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Ferumoxytol for treating iron deficiency anemia in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Hepcidin and iron metabolism: from laboratory to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Clinical studies of hip: An oral heme-iron product

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Hypoxia-inducible factors and the response to hypoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Hepcidin and disorders of iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Anti-vascular endothelial growth factor therapy for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Patient independence in chronic kidney disease and anaemia: implications of the 2012 KDIGO guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.941349

10.1586/17474086.2014.941349

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25025373